Long-term azithromycin therapy in severe COPD with repeated exacerbations Source: Annual Congress 2010 - COPD exacerbation Year: 2010
Six months azithromycin treatment in COPD patients with high risk of further exacerbations Source: International Congress 2017 – Management of COPD Year: 2017
Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations Source: Eur Respir J, 53 (4) 1900147; 10.1183/13993003.00147-2019 Year: 2019
Long-term effect of roflumilast on exacerbations in patients with severe to very severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 526s Year: 2006
Efficacy of azithromycin vs. ciprofloxacin in the treatment of patients with acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 544s Year: 2002
Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015
Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability Source: International Congress 2014 – Markers Year: 2014
The 1-year cost-effectiveness of roflumilast for the treatment of severe to very severe COPD patients Source: Eur Respir J 2007; 30: Suppl. 51, 194s Year: 2007
Two-year safety of targeted lung denervation in patients with moderate to severe COPD Source: International Congress 2015 – Bronchoscopic treatment of COPD and asthma: valves, coils, thermoplastics and something more Year: 2015
FEV1 is a sensible marker of healing after antibiotic treatment in severe COPD outpatients affected with AECB Source: Eur Respir J 2001; 18: Suppl. 33, 190s Year: 2001
Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013
Health status following an acute exacerbation of chronic bronchitis (AECB) is better in patients receiving gemifloxacin compared with clarithromycin Source: Eur Respir J 2001; 18: Suppl. 33, 542s Year: 2001
Effect of azithromycin treatment on inflammation in COPD patients Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019
Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
Efficacy of levofloxacin (LVF) in the treatment of acute exacerbations of chronic bronchitis (AECB) in patients with risk factors Source: Annual Congress 2003 - Acute exacerbations of asthma and COPD Year: 2003
Long-term safety of bilateral targeted lung denervation in patients with COPD in a single procedure Source: International Congress 2015 – Bronchoscopic treatment of COPD and asthma: valves, coils, thermoplastics and something more Year: 2015
Placebo-controlled, double-blind trial of chronic, intermittent ‘pulse‘ therapy of moxifloxacin to prevent acute exacerbations in COPD patients with chronic bronchitis: baseline data Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients Year: 2006
Influence of statin therapy on exacerbation frequency in patients with COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009
COPD on anti-GERD therapy remains at higher risk for severe exacerbation Source: International Congress 2014 – COPD exacerbations Year: 2014